A0650 A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)

Gautam T. Jayram; N. Shore; A. Salmasi; L. Aguilar; T.C. Burn; Christine Francis Lihou; Viraj Degaonkar; Erik T. Goluboff; D. Ganapathy; S. P. Lerner

doi:10.1016/s0302-2838(26)00701-3

A0650 A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)

European Urology 2026

View at publisher

Authors: Gautam T. Jayram, N. Shore, A. Salmasi, L. Aguilar, T.C. Burn, Christine Francis Lihou, Viraj Degaonkar, Erik T. Goluboff, D. Ganapathy, S. P. Lerner

DOI: 10.1016/s0302-2838(26)00701-3

Cited by: 0

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Urinary Bladder and Prostate Research Fibroblast Growth Factor Research

Publication details

Journal / source: European Urology
Volume: 89
Pages: S1–S1
Publication date: 13 February 2026
Language: EN